# Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

> **NCT06132828** · PHASE1 · RECRUITING · sponsor: **Zhejiang Doer Biologics Co., Ltd.** · enrollment: 216 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** DR30206

## Key facts

- **NCT ID:** NCT06132828
- **Lead sponsor:** Zhejiang Doer Biologics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-27
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 216 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06132828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06132828, "Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06132828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*